CoMoTeMS: Cognitive-motor Telerehabilitation in MS

Sponsor
Universitair Ziekenhuis Brussel (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05355389
Collaborator
National MS Center Melsbroek (Other), Research Foundation Flanders (Other)
90
3
34

Study Details

Study Description

Brief Summary

The primary goal of this project is providing evidence that a home-based combined cognitive-motor training program improves cognition in persons with multiple sclerosis (MS), compared to single cognitive and motor rehabilitation. Secondary goals are to assess the effects on walking performance and to identify the mechanisms of improvement and predictors of treatment response. The main backbone of this project will be a randomized controlled two-centre clinical trial, in which an at-home computerised cognitive-motor rehabilitation program using telemedicine aimed at improving working memory in persons with MS will be evaluated. Based on the information gathered during this trial, possible mechanisms of improvement will be identified by analysing anatomical and neurophysiological changes on structural MRI and resting-state and task-related EEG before and after rehabilitation. Furthermore, factors that can predict treatment response to the rehabilitation program will be identified.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Cognitive training
  • Behavioral: Motor training
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
90 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Patients will be randomly assigned to either the cognitive-motor, the cognitive or the motor telerehabilitation group, stratified by baseline activity level and cognition.Patients will be randomly assigned to either the cognitive-motor, the cognitive or the motor telerehabilitation group, stratified by baseline activity level and cognition.
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Masking Description:
The study will be double-blinded: patients will not be made aware of the rationale and predictions of the study. The teleconsultations will be carried out by a trained MS nurse, while the baseline and follow-up testing and analyses are carried out by an investigator who is blinded to the treatment allocation of the patients.
Primary Purpose:
Treatment
Official Title:
Cognitive-motor Telerehabilitation in Multiple Sclerosis
Anticipated Study Start Date :
Jul 1, 2022
Anticipated Primary Completion Date :
May 1, 2024
Anticipated Study Completion Date :
May 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: Cognitive-motor training group

Behavioral: Cognitive training
For the cognitive treatment intervention the widely used cognitive training program RehaCom will be used. This is a computer-aided program with more than 30 modules focusing on different domains of cognition. RehaCom has shown improvements in verbal learning, visuospatial memory, information processing speed, attention, executive functions, depression, fatigue and quality of life in PwMS (PMID 31927200, 28116167, 19825502, 23192417). Patients will train on their home computer without direct therapist supervision, using three RehaCom modules that are focused on improving working memory. Both patients in the combined intervention and the cognitive intervention group will be doing a 45-minute computer session respectively one and two days per week for a total of 12 weeks.
Other Names:
  • BrainStim
  • Behavioral: Motor training
    For the motor treatment intervention a patient-tailored aerobic training program will be used. Based on their baseline physical activity level patients can choose out of a number of aerobic activities of either mild, moderate or strenuous intensity, with a total training time of 90 minutes for the motor intervention group and 45 minutes for the combined intervention group, divided over at least two training sessions per week of at least 15 minutes per session. The training will be carried out individually at home, without therapist supervision. All physical activities will be logged using the sport watch equipped with a heart rate sensor and an accelerometer. Training intensity will be assessed using the patient's heart rate and the Rating of Perceived Exertion scale.

    Active Comparator: Cognitive training group

    Behavioral: Cognitive training
    For the cognitive treatment intervention the widely used cognitive training program RehaCom will be used. This is a computer-aided program with more than 30 modules focusing on different domains of cognition. RehaCom has shown improvements in verbal learning, visuospatial memory, information processing speed, attention, executive functions, depression, fatigue and quality of life in PwMS (PMID 31927200, 28116167, 19825502, 23192417). Patients will train on their home computer without direct therapist supervision, using three RehaCom modules that are focused on improving working memory. Both patients in the combined intervention and the cognitive intervention group will be doing a 45-minute computer session respectively one and two days per week for a total of 12 weeks.
    Other Names:
  • BrainStim
  • Active Comparator: Motor training group

    Behavioral: Motor training
    For the motor treatment intervention a patient-tailored aerobic training program will be used. Based on their baseline physical activity level patients can choose out of a number of aerobic activities of either mild, moderate or strenuous intensity, with a total training time of 90 minutes for the motor intervention group and 45 minutes for the combined intervention group, divided over at least two training sessions per week of at least 15 minutes per session. The training will be carried out individually at home, without therapist supervision. All physical activities will be logged using the sport watch equipped with a heart rate sensor and an accelerometer. Training intensity will be assessed using the patient's heart rate and the Rating of Perceived Exertion scale.

    Outcome Measures

    Primary Outcome Measures

    1. Change in Digit span backwards [0 weeks, 12 weeks, 24 weeks, 64 weeks]

      Measure of working memory

    Secondary Outcome Measures

    1. Change in Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) [0 weeks, 12 weeks, 24 weeks, 64 weeks]

      Measure of cognition in MS

    2. Change in Corsi backwards [0 weeks, 12 weeks, 24 weeks, 64 weeks]

      Measure of working memory

    3. Change in 6-Minute Walk Test (6MWT) [0 weeks, 12 weeks, 24 weeks, 64 weeks]

      Measure of walking performance

    4. MRI T1 3D BRAVO scan [0 weeks, 12 weeks, 24 weeks]

      Cortical volume, volumes of white matter and deep grey matter

    5. MRI T2 FLAIR 3D Cube scan [0 weeks, 12 weeks, 24 weeks]

      Lesion volume

    6. Diffusion weighted image (DWI) [0 weeks, 12 weeks, 24 weeks]

      structural connectivity using graph theoretical measures

    7. Synthetic MRI [0 weeks, 12 weeks, 24 weeks]

      Contrast weighted images based on measurements of tissue properties from a single acquisition

    8. resting-state EEG [0 weeks, 12 weeks]

      functional connectivity using graph theoretical measures

    9. task-related EEG - auditory oddball paradigm [0 weeks, 12 weeks]

      functional connectivity using graph theoretical measures, event-related potentials

    10. task-related EEG - adjusted SDMT paradigm [0 weeks, 12 weeks]

      functional connectivity using graph theoretical measures, event-related potentials

    11. task-related EEG - n-back paradigm [0 weeks, 12 weeks]

      functional connectivity using graph theoretical measures, event-related potentials

    Other Outcome Measures

    1. Change in Hospital Anxiety and Depression Scale (HADS) [0 weeks, 12 weeks, 24 weeks, 64 weeks]

      Measure of anxiety and depression

    2. Change in Fatigue Scale for Motor and Cognitive functions (FSMC) [0 weeks, 12 weeks, 24 weeks, 64 weeks]

      Measure of fatigue in MS

    3. Change in Visual Analogue Scale (VAS) [0 weeks, 12 weeks, 24 weeks, 64 weeks]

      VAS on the impact of perceived cognitive symptoms on daily life

    4. Change in 36-Item Short Form Survey (SF-36) [0 weeks, 12 weeks, 24 weeks, 64 weeks]

      Measure of quality of life Only Dutch-speaking participants

    5. Change in Multiple Sclerosis Impact Scale-29 (MSIS-29) [0 weeks, 12 weeks, 24 weeks, 64 weeks]

      Measure of quality of life in MS Only Dutch-speaking participants

    6. Change in Multiple Sclerosis-59 (SEP-59) [0 weeks, 12 weeks, 24 weeks, 64 weeks]

      Measure of quality of life, combination of SF-36 and MS-specific questions Only French-speaking participants Of note, the French title of this questionnaire is Sclérose En Plaques-59.

    7. Change in Cognitive Leisure Activity Scale (CLAS) [0 weeks, 12 weeks, 24 weeks, 64 weeks]

      Measure of baseline cognitive activities

    8. Change in Godin Leisure-Time Exercise Questionnaire (GLTEQ) [0 weeks, 12 weeks, 24 weeks, 64 weeks]

      Measure of baseline physical activities

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 65 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Clinically definite multiple sclerosis (revised McDonald criteria 2017)

    • Expanded Disability Status Scale (EDSS) below 6.0

    • Digit span backwards z-score between [-3 and -0.5] standard deviations below the median of the normative values

    • Age between 18 and 65

    • Able to safely perform motor rehabilitation in the home situation (assessed by rehabilitation physician and/or occupational or physiotherapist)

    Exclusion Criteria:
    • Cognitive rehabilitation within six months before inclusion

    • Inpatient multidisciplinary rehabilitation program within three months before inclusion or planned inpatient program during trial

    • Start of or switch in immunomodulator treatment within three months before inclusion

    • Less than one month post-exacerbation

    • Major psychiatric or medical disorder that could influence cognitive functions

    • Combined vision with optimal correction below 0.6 on Snellen Visual Acuity Test

    • Unable or unwilling to undergo EEG or MRI

    • Refusing informed consent

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Universitair Ziekenhuis Brussel
    • National MS Center Melsbroek
    • Research Foundation Flanders

    Investigators

    • Principal Investigator: Guy Nagels, Vrije Universiteit Brussel, Universitair Ziekenhuis Brussel

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Universitair Ziekenhuis Brussel
    ClinicalTrials.gov Identifier:
    NCT05355389
    Other Study ID Numbers:
    • CoMoTeMS
    • 1SD5322N
    First Posted:
    May 2, 2022
    Last Update Posted:
    May 2, 2022
    Last Verified:
    Apr 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Universitair Ziekenhuis Brussel
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of May 2, 2022